Member Info for ak_gabba

The Times have an article

https://www.thetimes.co.uk/article/health-chiefs-sue-novacyt-for-134m-366pxjt38

Quote from novacyt

Novacyt said it “continues to believe it has strong grounds to defend the claim and assert its contractual rights, including in relation to recovering outstanding sums due from the DHSC”

I doubt we will get anymore out of Novacyt

No need to apologise poidster. No offence was taken :-) Without knowing the basis of the dispute and claim we are all at a loss to explain. I think we will just get the usual responses on Thursday of strong grounds to exert contractual rights and can't say anything for legal reasons. It's extremely frustrating

That doesn't fit with what you were indicating though. Today was about the rns relating to the dhsc contract irrespective to your opinion on covid being over

I'm not suggesting that text indicates swapping just that if a different product was available it would be the same price or less than the previous one. If you read that text outside of a dispute its easier to read :-)

For what it's worth my interpretation of the dispute and recent claim from dhsc is that they want reimbursed for the non promate product. Exsig direct. Not sure under what grounds they are claiming as it was approved delivered and at least partially used.
We have been told Exsig direct is still waiting ctda approval and the ifu has been recently updated. We know promate has either been approved or on the temporary control list.

GDWK,

Yes thats part of 5.2 variations to goods.

5.2 Due to rapidly evolving nature of the COVID-19 response, updated and improved versions of the Goods may be developed/launched in the future which the Authority may wish to purchase. The parties agree that where such new products are made available by the supplier, they may be ordered by the Authority under the terms of this agreement at the same price per reaction as (or less than) the price listed for the original good"

Depends on interpretation really however I read that as buying a developed/launched product at the same price as the previous product or less if the developed/launched product is less than the previous.

According to DA we are waiting on an update this month regarding the strategy of the company. Will be interesting to see which products we are looking to launch before the end of this year. Hopefully some non covid products aligned with the increased workflows that PROmate provide. I'm also hopeful of understanding what R&D they have been working on.

Wilson,
Honest answer is nobody outside of the process knows. It was however good to see in table format the current status of all tests submitted from Novacyt to CTDA for review.

Exmex,
Very well spotted! I hadn't noticed that and yes that is the big question!

I have links to the IFUs from issue 6 - 11. unable to find earlier issues at the moment.

https://www.primerdesign.co.uk/assets/files/path_promate_covid_19_ce_sted_ifu_issue_600.pdf
http://www.primerdesign.co.uk/assets/files/path_promate_covid_19_ce_sted_ifu_issue_7_00.pdf?timestamp=1619262149
http://www.primerdesign.co.uk/assets/files/path_promate_covid_19_ce_sted_ifu_issue_8_00.pdf?timestamp=1624187376
http://www.primerdesign.co.uk/assets/files/path_promate_covid_19_ce_sted_ifu_issue_9_00.pdf?timestamp=1625059922
https://www.primerdesign.co.uk/assets/files/path_promate_covid_19_ce_sted_ifu_issue_10_00_2.pdf?timestamp=1649690642
https://www.primerdesign.co.uk/assets/files/path_promate_covid_19_ce_sted_ifu_issue_11_00.pdf?timestamp=1649387360

The software for the Q32 remains the same from IFU 6 - 10 but changes in IFU 11. Goes from 1.2.2 to 1.5 or later (giving scope for further releases). I'm perhaps adding 2 + 2 and not getting 4 here but I'm wondering if there have been software revision changes to support greater workflow and provide better lab support?

here is the link to IFU 11 which is mentioned in the CTDA protocol spreadsheet

https://www.primerdesign.co.uk/assets/files/path_promate_covid_19_ce_sted_ifu_issue_11_00.pdf?timestamp=1649387360

you have a fair point there John!

PROmate q32 just been added to CTDA list

https://twitter.com/Larry64450205/status/1513528557733089281

https://www.gov.uk/government/publications/covid-19-test-validation-approved-products?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=e9ac3df4-121c-4c48-9b2d-726ad3b008b8&utm_content=immediately#full-publication-update-history

Spotted by larry and growhydrodude1

https://www.theyworkforyou.com/wrans/?id=2022-03-03.133999.h&s=Pcr+testing+in+the+nhs#g133999.q0

Direct link. Looks like moving from national contract to individual trust requirements

"This event is taking place this week in Birmingham, but I can't find Novacyts name on the list of exhibitors.
https://congress.ibms.org/ibms-congress-2022/programme.html
Were they a late entry to the event?"

Exmex, they were at the 2019 IBMS congress exhibition. It's odd that they go to exhibitions abroad but don't attend the IBMS congress. I can only fathom a guess that they didn't attend due to the on-going dispute

The baseline SP for the LTIP is £3.54. his average is just below that now

Averaged down indeed

Shares Avg Price Cost
10000 £8.953 £89,530.00
39670 £2.020 £80,133.40
Totals
49670 £3.416 £169,663.40

hi Kaeren, thanks for the link and share from rick. thats a very useful article and interesting to see the software side of it explained

It was mentioned that revenue from Covid sales may be reduced by 50% in 2022.

See the outlook below taken from the RNS on 25th Jan 2022

https://www.lse.co.uk/rns/NCYT/strategy-and-full-year-2021-trading-update-qgoeql7ul3x7i26.html

"2022 outlook

As observed over the last two years, and highlighted in the last two months, the course of this pandemic is unpredictable and so, therefore, is the predictability of testing demand. Currently, the Board expects COVID-19 reported sales could be reduced by around 50% in 2022, versus 2021, which will be partially offset by new non-COVID-19 products which will start to come onstream in Q4 2022."

thanks for that link Kaeren, Really interesting. You can play around with the filters. here are 2

https://www.volza.com/imports-global/global-import-data-of-genesig

https://www.volza.com/imports-global/global-import-data-of-primer+design-primerdesign

Thanks to larry for spotting the CTDA update and posting this on twitter

https://twitter.com/Larry64450205/status/1496885787459264513

New Forms Research has also posted screenshots of the list of tests.

The protocol has been updated today which will be effective from 1st March 2022 and continue until 31st May 2022.

https://www.gov.uk/government/publications/covid-19-test-validation-approved-products

https://www.gov.uk/government/publications/covid-19-test-validation-approved-products/medical-devices-regulations-2002-protocols-effective-from-1-march-2022

here is the list of current approved lft tests which have passed phase 3a. biosynx is there

https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/outcome-of-the-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices